



Neuronetics Inc.

Announcement

Neuronetics Announces

NBC 7 NEWS HEALTHCAST- BOSTON, MA - JUNE 2, 2010

NEUROSTAR TMS THERAPY FOR MAJOR DEPRESSIVE DISORDER

<http://www1.whdh.com/features/articles/healthcast/BO143311/>

Oscar Morales, M.D., McLean Hospital - Associate Director,
Psychiatric Neurotherapeutics Program (PNP)
Director, Transcranial Magnetic Stimulation (TMS)
Service

"When it comes to treating depression, medication isn't always the answer. Now, McLean Hospital is offering an alternative to anti-depressants. 7's Christa Delcamp explains."

The Psychiatric Neurotherapeutics Program (PNP) at McLean Hospital specializes in the neuromodulatory and neurostimulatory treatment of psychiatric disorders. It offers transcranial magnetic stimulation (TMS), a new and promising method for treating severe depression, as well as electroconvulsive therapy (ECT), a highly effective conventional intervention for chronic depression, mania, catatonia and schizophrenia. TMS and ECT are the first in a line of clinical services to be offered through the program.



U.S. News & World Report ranked McLean Hospital first among all freestanding psychiatric hospitals. McLean Hospital is the largest psychiatric facility of Harvard Medical School, an affiliate of the Massachusetts General Hospital and a member of Partners HealthCare.

NeuroStar TMS Therapy is
the first and only non-systemic and non-invasive treatment for patients who have


not received satisfactory improvement from 1 prior antidepressant medication, cleared by the FDA in

October 2008.

NeuroStar TMS Therapy: How it Works

Treatment with NeuroStar TMS Therapy activates nerve cells in an area of the brain that is thought to be linked to depression, by delivering highly focused MRI-strength magnetic field pulses.

The treatment is a 40-minute outpatient procedure that is performed under supervision of a psychiatrist, does not require anesthesia or sedation, and is administered daily for 4-6 weeks. NeuroStar TMS Therapy may not be effective for all patients with depression.



NeuroStar TMS Therapy: Key Facts

- The NeuroStar TMS Therapy system was cleared by the FDA in October 2008. NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
- In a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapysystem to an inactive device, patients treated with active NeuroStar TMS Therapy experienced a 22.1% average reduction of their depression symptoms, compared to a 9% average reduction of depression symptoms in patients receiving inactive treatment.
- In an open-label clinical trial, which is most like real world clinical practice, approximately 1 in 2 patients experienced significant improvement in symptoms, and 1 in 3 experienced complete symptom resolution.¹
- There were no systemic side effects observed with TMS Therapy, such as weight gain and sexual dysfunction. The most common adverse events related to treatment were scalp pain or discomfort at the treatment area during active treatments.

www.neurostartms.com

 Send to a Colleague